INCY Overview — StockExplainer

-42%

-5.3% per year

Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.

Country US

Exchange NASDAQ

Industry Biotechnology

Sector Healthcare

Market Cap $13.85B

CEO Mr. Herve Hoppenot

Incyte Corporation is a biotechnology company that creates medicines to treat serious diseases, especially types of cancer and blood disorders. They have developed several important drugs, including JAKAFI, which helps patients with certain blood cancers. Incyte is also working on new treatments that are still being tested to help patients with various types of cancer and other health conditions. The company partners with other organizations to advance their research and bring new therapies to market.

Streams of revenue

OPZELURA: 35%

J A K A F I: 29%

Olumiant Royalty: 9%

M I N J U V I: 8%

I C L U S I G: 8%

PEMAZYRE Royalty Revenues: 5%

Milestone And Contract Revenue: 5%

Tabrecta Royalty Revenues: 2%

ZYNYZ: 0%

Geographic Distribution

Non Us: 100%

Core Products

💊

Jakafi Blood disorder treatment

🧬

Monjuvi Lymphoma therapy

🧴

Opzelura Eczema cream

💉

Pemazyre Cholangiocarcinoma drug

Business Type

Business to Business

Competitive Advantages

🔍

Focus on Niche Markets Incyte focuses on specialized therapeutic areas, such as rare cancers and chronic conditions, allowing it to dominate niche markets with less competition.

🤝

Collaborative Partnerships Strategic collaborations with major pharmaceutical companies enhance research capabilities and facilitate access to new markets and technologies.

🌍

Established Market Presence With successful products like JAKAFI, Incyte has established a strong market presence and brand recognition in the biopharmaceutical industry.

🧬

Strong Pipeline of Therapies Incyte has a diverse portfolio of clinical-stage products targeting various cancers and diseases, providing a robust pipeline that can lead to significant future revenue.

📜

Intellectual Property Portfolio A strong portfolio of patents protects Incyte's innovations, providing a competitive edge and reducing the risk of generic competition.

Key Business Risks

⚖️

Regulatory Risk Changes in regulatory requirements or delays in drug approvals can significantly impact product launch timelines and revenue.

🏁

Competitive Risk Incyte faces intense competition from other biopharmaceutical companies, which could affect market share and pricing power.

🚚

Supply Chain Risk Disruptions in the supply chain for raw materials or production can hinder the availability of products, affecting revenue.

🧪

Clinical Trial Risk Failure of clinical trials for ongoing product candidates can lead to substantial financial losses and affect future development plans.

📉

Market Acceptance Risk New products may not gain sufficient market acceptance, impacting sales projections and overall profitability.

Meeting Expectations

3 /10

Higher values indicate better execution and credibility

Business Overview

Performance Analysis

Stock Price

Performance Analysis

Stock Price